Symptom Management and Supportive Care

The following activities are available for studies related to the use of antibiotics, growth factors, or other interventions to limit treatment side effects.

• Osteonecrosis of the Jaw in Patients with Bone Metastases Treated with Bisphosphonates: A Retrospective Study
• Prevention of Docetaxel- or Paclitaxel-Associated Taste Alterations in Cancer Patients with Oral Glutamine: A Randomized, Placebo-Controlled, Double-Blind Study
• Cancer Treatment-Induced Bone Loss: Pathophysiology and Clinical Perspectives
• Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers
• The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: Strategies for Improving VTE Prophylaxis in Hospitalized Cancer Patients
• Efficacy and Safety of Erythropoiesis-Stimulating Proteins in Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis
• Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present, and Future Recommendations
• Amifostine: The First Selective-Target and Broad-Spectrum Radioprotector
• Management and Preparedness for Infusion and Hypersensitivity Reactions
• Early Intervention With Epoetin Alfa During Platinum-Based Chemotherapy: An Analysis of Quality-of-Life Results of a Multicenter, Randomized, Controlled Trial Compared With Population Normative Data AND Early Intervention With Epoetin Alfa During Platinum EXPIRED
• Evaluating the Total Costs of Chemotherapy-Induced Febrile Neutropenia: Results from a Pilot Study with Community Oncology Cancer Patients
• Neutropenic Events in Community Practices Reduced by First and Subsequent Cycle Pegfilgrastim Use
• Bone Loss and Fracture Risk Associated with Cancer Therapy
• Patients Previously Transfused or Treated with Epoetin Alfa at Low Baseline Hemoglobin Are at Higher Risk for Subsequent Transfusion: An Integrated Analysis of the Canadian Experience EXPIRED
• Management of Cancer-Related Anemia in Patients with Breast or Gynecologic Cancer: New Insights Based on Results from the European Cancer Anemia Survey EXPIRED
• HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum EXPIRED
• Warfarin Versus Low Molecular Weight Heparin Therapy in Cancer Patients EXPIRED
• The Erythropoietin Receptor and Its Expression in Tumor Cells and Other Tissues EXPIRED
• The Role of Hypoxia-Induced Factors in Tumor Progression EXPIRED
• rHuEPO and Treatment Outcomes: The Clinical Experience EXPIRED
• rHuEPO and Treatment Outcomes: The Preclinical Experience EXPIRED
• Tumor Hypoxia: Causative Factors, Compensatory Mechanisms, and Cellular Response EXPIRED
• Hypoxia and Anemia: Factors in Decreased Sensitivity to Radiation Therapy and Chemotherapy? EXPIRED
• rHuEPO and Improved Treatment Outcomes: Potential Modes of Action EXPIRED
• Adjuvant Analgesics in Cancer Pain Management EXPIRED
• Management of Bleeding in Patients with Advanced Cancer EXPIRED
• Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid EXPIRED
• Thrombotic Complications of Central Venous Catheters in Cancer Patients EXPIRED
• The Evolving Role of Epoetin Alfa in Cancer Therapy EXPIRED
• Epoetin Alfa 60,000 U Once Weekly Followed by 120,000 U Every 3 Weeks Increases and Maintains Hemoglobin Levels in Anemic Cancer Patients Undergoing Chemotherapy EXPIRED
• Complementary and Alternative Therapies for Cancer EXPIRED
• Chronic Pain Following Treatment For Cancer: The Role of Opioids EXPIRED
• Cancer Fatigue: The Way Forward (Available Credits: 4) (4 activities)
• Baseline and Early Treatment Factors Are not Clinically Useful for Predicting Individual Response to Erythropoietin in Anemic Cancer Patients EXPIRED
• 5-HT³-Receptor Antagonists for the Treatment of Nausea and Vomiting: A Reappraisal of Their Side-Effect Profile EXPIRED
• Managing Anemia in the Cancer Patient: Old Problems, Future Solutions EXPIRED
• Comparable Efficacy of Epoetin Alfa for Anemic Cancer Patients Receiving Platinum- and Nonplatinum-Based Chemotherapy EXPIRED